Ojjaara to treat myelofibrosis in adults with anemia
Drug Name: Ojjaara Active Ingredient: momelotinib Indications: To treat intermediate or high-risk myelofibrosis in adults with anemia Approval Date: 9/15/2023 Company: GlaxoSmithKline More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216873s000lbl.pdf